Chargement en cours...
Assessment of pazopanib-related hypertension, cardiac dysfunction and identification of clinical risk factors for their development
BACKGROUND: Antineoplastic therapy with the tyrosine kinase inhibitor pazopanib in patients with advanced/metastatic renal cell carcinoma (mRCC) has been associated with hypertension (HTN), cardiomyopathy, and cardiac dysrhythmias. We therefore assessed the cardiovascular (CV) risk with pazopanib in...
Enregistré dans:
| Publié dans: | Cardiooncology |
|---|---|
| Auteurs principaux: | , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
BioMed Central
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5828231/ https://ncbi.nlm.nih.gov/pubmed/29497565 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40959-017-0024-8 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|